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The optimization of the diagnostic work-up in 
patients with suspected obstructive lung disease
Frank J Visser1*, M ilena JM M  van der V e g t1, Gert Jan van der W ilt2, Julius P Janssen1
Abstract
Background: Pulmonary function testing is a key procedure in the work-up of patients who are suspected of 
having asthma and chronic obstructive lung disease (COPD). Therein, clinical visits and pulmonary function tests 
(PFTs) are the major contributors to the overall financial costs.
The aim of this study was to assess whether a specific diagnostic test protocol contributes to the optimization of 
the work-up of patients who are suspected of having asthma and COPD.
Methods: A prospective, single-blind, and randomized controlled study was performed. In the control group (CG), 
all of the PFTs that were ordered by the lung specialist were carried out. In the experimental group (EG), specific 
PFTs were selected according to our protocol. The primary end point was the total cost of achieving a final 
diagnosis.
Results: One hundred and seventy-nine patients were included into this study: 86 in the CG and 93 in the EG. The 
mean number of tests to diagnosis was 3.8 in the CG versus 2.9 in the EG (P < 0.001). The mean number of 
redundant PFTs before diagnosis was 1.2 in the CG versus 0.08 in the EG (P < 0.001). The number of patients who 
required an additional outpatient visit to complete diagnosis was higher in the CG in comparison to the EG (P =
0.02). The mean cost of work-up per diagnosis was €227 in the CG versus €181 in the EG (P < 0.001).
Conclusions: In this group of patients with suspected obstructive lung disease, protocol-driven, PFT-based 
selection is more cost-effective than test selection at the discretion of lung physicians.
Background
Diagnosing asthma and COPD is an important part of 
the daily practice of pulmonary physicians. Pulmonary 
function tests (PFTs) play a key role in the work-up of 
obstructive pulmonary diseases [1-3].
No exact figures exist for the annual costs that are 
associated with current diagnostic processes, although 
they are likely to be substantial.
Finding the optimal diagnostic work-up in patients 
with obstructive lung disease is challenging. A physician 
who routinely orders most or all PFTs in the work-up 
of asthma and COPD patients runs the risk of unneces­
sary testing; however, a physician who orders tests more 
sparingly runs the risk of unnecessary outpatient 
visits. In view of the high incidence of patients with
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obstructive lung diseases, it is im portant to find the 
optimal diagnostic work-up in each of these patients. To 
this end, we have developed a diagnostic protocol (Fig­
ure 1) that can be jointly used by physicians and pul­
m onary function assistants. In our group, some 
physicians already use this diagnostic PFT protocol; 
however, some of the physicians order PFTs without fol­
lowing the prescribed diagnostic PFT protocol. Prior to 
the beginning of this study, there was no available evi­
dence that dem onstrated that protocol-driven PFT 
ordering is more efficient than physician-driven test 
ordering. Therein, we hypothesize that protocol-driven 
test ordering will be more efficient than test ordering 
without direction from a diagnostic protocol.
The aim of this study was to assess whether protocol- 
driven test ordering reduces the number of redundant 
pulmonary function tests, decreases the number of out­
patient visits, and increases the cost effectiveness of 
patient work-up in comparison to physician-driven test 
ordering.
© 2010 Visser e t al; licensee BioMed Central Ltd. This is an Open Access article d is trib u te d  under the  te rm s o f the  Creative Com m ons 
A ttr ib u tio n  License (h ttp ://c rea tivecom m ons.o rg /licenses /by /2 .0 ), w h ich  perm its  unrestric ted  use, d is tribu tion , and rep rod u c tion  in 
any m ed ium , p rov ided  th e  o rig in a l w o rk  is p rope rly  c ited.
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F igure  1 Pulm onary fu n c tio n  p ro toco l fo r obs truc tive  diseases. Criteria for obstruction, airway responsiveness (PC20 histamine), reversibility, 
and steroid tests (see text).
Methods
A prospective, randomized, and single-blind trial was 
conducted at our outpatient unit.
An institutional review board (IRB) approved this 
study. This study was only a formal stratification of the 
current practice; hence, inform ed consent was not 
necessary.
Methods
The study participants consisted of consecutive adult 
patients who were referred to our respiratory outpatient 
clinic and suspected to have asthma or COPD at the 
end of the first outpatient visit. None of the patients 
had recently (in the preceding three years) been diag­
nosed with asthma or COPD by a pulmonary physician. 
Patients were primarily referred by general practitioners; 
however, two patients referred themselves to our out­
door department, and three were referred by cardiolo­
gists. We excluded patients who were not able to 
adequately complete pulmonary function tests, were 
referred to a pulmonary physician because of an abnor­
mal X-ray, needed pre-operative consultations, and have 
had an infection of the upper or lower airways or a pos­
sible exacerbation of obstructive airway disease in the 
past two months.
In the first visit, the physician takes a medical history, 
performs a physical examination, makes a differential 
diagnosis, and orders laboratory testing, such as a chest
X-ray. Only patients who were most likely to be diag­
nosed with asthma or COPD were included into this 
study. Physicians ordered diagnostic tests as they 
deemed appropriate and added the reason for the pul­
monary function testing (e.g. suspected obstructive lung 
disease). At the end of the first outpatient visit, nurses 
randomized the patients into the control group (work­
up at the discretion of the physician) or the experimen­
tal group (work-up in accordance with the protocol) by 
pulling an opaque envelope.
PFT lab assistants were notified of the outcome of the 
randomization in order to allow them to perform inves­
tigations as ordered or per protocol.
The PFT- protocol is shown in Figure 1. Therein, 
when the forced vital capacity (FVC) is less than normal, 
a total lung capacity (TLC) measurement was conducted 
in order to exclude restrictive lung disease. W hen the 
patients smoked more than 10 pack years, then their 
respective diffusion capacities were measured.
A second physician independently examined the 
results for each patient and classified the patients as 
follows:
Completely reversible (CR)
(1) An airway obstruction that is completely reversible 
(FEV1 reversible by > 9% of the predicted value) to a 
normal range after beta-2 agonist and anticholinergic 
treatment; patients who received reversibility testing
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were tested for both bronchodilators; (2) An airway 
obstruction that is completely reversible after 14 days of 
30 mg/day of prednisone; and (3) normal PFTs but a 
decreased PC20 histamine threshold.
This PFT group supports to the diagnosis of asthma.
Non-reversible obstructive (NRO)
Reduced FEV1 and FEV1/FVC values, which are irrever­
sible after beta-2 agonist and/or anti-cholinergic treat­
ment (an FEV1 increase of < 9% of the predicted value) 
and no return  to the norm al range after 10 days of 
30 mg/day of prednisone.
This PFT group supports the diagnosis of COPD.
Partly Reversible Obstructive (PRO)
Reversibility is present, but an airflow limitation persists. 
FEV1 increases by > 9% of the predicted normal value 
but does not re turn  to a norm al range after 
bronchodilators.
This PFT group supports the diagnosis of asthma with 
persistent airflow lim itation or COPD with partly 
reversibility.
Normal PFT group
No airflow lim itation and a norm al PC20 histamine 
threshold.
This group does not support the diagnosis of obstruc­
tive lung disease; hence, a different diagnosis must be 
considered.
The second physician assessed if the appropriate tests 
were conducted according to the diagnostic flow and 
decided on the pulmonary function classification. He 
assessed the decision about the final diagnosis of the 
PFT-referring physician.
The second physician calibrated his findings with the 
findings of the PFT-ordering physician only if there 
were conflicting findings. In all of these cases, we 
achieved a consensus on the final diagnosis.
COPD and asthma were finally diagnosed by the first 
physician on the basis of medical history (smoking 
behavior, allergies, a family history of asthma, and/or a 
pre-existing childhood condition); PFTs and clinical 
investigations, such as the eosinophil count; and the 
radioallergosorbent (RAST) test.
In the protocol, the criteria for obstruction included 
an FEV1 < normal and an FEV1/FVC < normal accord­
ing to Quanjer et al. [4]. Airway hyperresponsiveness 
was defined as PC20 histamine < 4 mg/ml [5]. Reversi­
bility was defined as a >9% improvement in the FEV1 in 
comparison to a predicted normal value [6-8]. Steroid 
tests consisted of 30 mg/day of prednisone for 10 days 
with the intent of reversing the FEV1 to normal levels, 
as advised by the Dutch Committee: diagnosis for 
asthma and COPD [7].
Forced vital capacity (FVC), forced expiratory volume 
in one second (FEV1), and airway responsiveness (PC20 
Histamine) were measured according to ERS criteria [1].
During the follow-up visit, the results of all of the 
investigations that were carried out at the discretion of 
the physician or according to the protocol were available 
to the physician who then decided whether a final diag­
nosis could be made. Follow-up visits and additional 
PFTs were scheduled as deemed appropriate.
Redundant PFTs were defined as tests that were not 
absolutely necessary to establish a final diagnosis. For 
example, a reversible obstructive PFT made the hista­
mine provocation test redundant, whereas a normal flow 
volume curve made the reversibility test redundant.
The economic analysis was conducted from a health 
care perspective that included only direct medical costs. 
Where available, unit cost prices were derived from a 
national guideline for the economic analysis of health 
care services [9]. In other instances, real cost prices 
were calculated on the basis of hospital administration 
data (Table 1).
Statistical analysis
The unpaired t test with Welch's correction was used to 
test for the statistical significance of differences between 
the two groups. An alpha of 0.05 or less was considered 
to be significant. For statistical calculations, we used 
GraphPad Prism5 for Microsoft Windows http://www. 
graphpad.com.
Results
From a total of 183 patients, 179 patients were included 
in this study: 86 patients in the CG and 93 patients in 
the EG. Four patients were excluded for the following 
reasons: one patient had a malignancy, one patient failed 
to follow-up, one patient died within a week of the start 
of the study, and the protocol was not followed with 
one patient. The second physician calibrated his findings 
with the findings of the PFT-ordering physician only if 
there were conflicting findings. In all of these cases, we 
achieved a consensus on the final diagnosis.
Table 2 summarizes patient characteristics at baseline. 
Classification of PFT groups on the basis of PFT results
Table 1 The cost of PFTs and follow-up visits
Tests Cost
Flow volume curve €15,00
Reversibility (bronchus dilators) testing €18,00
TLCO (diffusion capacity) €41,00
Hyper reactivity (histamine) €84,00
TLC €41,00
Outpatient visit €41,00
Steroid test €33,00
Visser et al. BMC Pulmonary Medicine 2010, 10:60
http://www.biomedcentral.com/1471-2466/10/60
Page 4 o f 6
Table 2 Patient characteristics
Contro l g roup  Experim ental g roup
Number o f patients 86 93
Avg. age (years) 55.4 56.8
Sex (% male) 45 46
Height 168.4 170.8
FEV1% pred. 77.8 78.0
FVC % pred. 91.3 91.0
Non-smoker 41% 38%
Ex-smoker 20% 23%
Current smoker 33% 29%
Unknown smoker 6% 10%
and final diagnoses are presented in Table 3. In the 
control group, 35 patients were diagnosed with asthma 
versus 39 patients in the experimental group. For the 
non-reversible obstructive group, these numbers were 
eight and nine patients, respectively. For the partly- 
reversible obstructive group, these numbers were 12 and 
14, respectively.
Diagnosis in the normal PFT group consisted of sar­
coidosis (1), gastroesophageal reflux (GER) (5), rhinitis 
and/or sinusitis (7), hyperventilation syndrome (3), per­
sistent cough (15/21 were smokers or ex-smokers), and 
dyspnea (3/8 were smokers).
On the basis of clinical assessment, 52 patients were 
found to have COPD with the following classifications: 
7 patients in GOLD stage 1, 24 patients in stage 2, 13 
patients in stage 3, and 8 patients in stage 4.
The total cost of the procedures that were used to 
reach a final diagnosis in patients who were suspected 
of having obstructive lung diseases.
In the control group, the mean total cost of testing 
and outpatient visits per diagnosis were €227.17, 
whereas, in the experim ental group, this cost was 
€180.89 (Figure 2, P < 0.001), which is a 20% reduction 
in cost.
Table 3 Classification on the basis of PFT results and 
final diagnoses
Classification on the  basis o f PFT C ontro l
g roup
Experim ental
g roup
Completely reversible obstructive 41% 42%
(CRO)
Non-reversible obstructive (NRO) 17% 17%
Partly reversible obstructive (PRO). 14% 15%
Normal PFT (NO) 27% 26%
Final diagnosis
Asthma 41% 42%
Asthma partly- reversible 5% 1%
COPD non- reversible- 17% 17%
COPD partly- reversible 10% 14%
Other diagnosis 27% 26%
The number and cost of outpatient visits until diagnosis
In the control group, two outpatient visits were needed 
to reach a final diagnosis in 71 patients, whereas 15 
patients needed three outpatient visits (mean 2.17, med­
ian 2). In the experimental group, 90 patients had two 
visits, and 3 patients had three visits (mean 2.03, median 
2). The difference in total visits between these groups 
was statistically significant (P = 0.02). Mean costs were 
€88.80 in the control group and €83.00 in the experi­
mental group (Figure 2, P = 0.02).
The number and cost of the PFTs that were needed 
for diagnosis:
In the control group, a mean number of 3.81 PFTs per 
patient was necessary in order to diagnose asthma or 
COPD. In the experimental group, a mean number of 
2.94 tests was necessary (Figure 2, P < 0.001). In the 
control and experimental groups, the mean costs of 
PFTs were €138.37 and €97.89, respectively (P < 0.001).
The number and cost of the redundant PFTs that were 
used for diagnosis
In the control group, a mean of 1.20 redundant PFTs 
per patient were performed. In the experimental group, 
a mean of 0.08 unnecessary PFTs were performed (P <
0.001). The mean costs of redundant tests for diagnoses 
in the control and experimental groups were €51.35 and 
€3.30, respectively (Figure 2).
Histamine provocation tests and the added cost of 
reversibility testing were the two m ost im portant 
sources of redundant costs (Table 4).
Time until final diagnosis
In the control group, a mean number of 33.02 days was 
necessary to reach a final diagnosis, whereas in the 
experimental group, a mean number of 35.94 days was 
needed (P = 0.51).
Post-hoc
We evaluated the added value in making a diagnosis of 
asthma using the steroid test in our patients. Conform­
ing to the protocol, we needed 11 steroid tests in the 
control group and 10 steroid tests in the experimental 
group. Patient diagnoses did not change with the addi­
tion of these steroid tests.
Discussion
The main finding of our study is that the introduction 
of a problem -oriented protocol for ordering PFTs in 
patients with suspected obstructive pulmonary disease 
can reduce the number of redundant PFTs and outpati­
ent visits, which results in a 20% decrease in costs with­
out an increase in time to final diagnosis. Given the 
high frequency of PFT usage for the diagnosis of 
obstructive lung disease, this observed decrease in cost
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F igure 2 Mean cost per pa tien t per diagnosis. Redund. = Redundant.
results in a substantial savings at a population level. In 
our practice of 600 patients per year with suspected 
obstructive lung disease, protocol-guided test ordering 
can lead to an annual cost reduction of €27,768 = 
€46.28 per patient. The most im portant part of these 
potential savings is a reduction in the need for reversi­
bility testing when a norm al flow volume curve is 
obtained and a reduction in the need for the tim e­
consuming Our lung function protocol is based on 
the asthma and COPD guidelines [7] of the Nether­
lands and is w ithin the ERS and ATS standards 
[3,4,6,10]. Therefore, many other countries can use 
our protocol with slight modifications. Our patients 
with asthma and COPD are demographically similar 
to other western European countries, the USA, and 
Canada. The only difference is that most patients 
were referred to us from a family doctor, as is typi­
cally the case in the UK; however, in some other 
countries, a family physician may be skipped more
Table 4 Redundant PFTs
Redundant PFT C ontro l g roup Experim ental g roup
N um ber (%) Cost in € N um ber (%) Cost in €
Histamine 
provocation test
19 (22) 1596 1 (1) 84
Reversibility testing 3 o 3 ) 540 1 (1) 18
TLC 30 (35) 1230 3 (3) 123
Diffusion capacity 
for CO
24 (28) 984 2 (2) 82
Totals 103 (120) 4323 7(8) 307
often. Therefore, a minor selection bias is possible; 
however, the diagnostic criteria for COPD or asthma 
do not depend on the patient’s physician. Of course, 
the skills and the tools are different between general 
practitioners (GPs) and pulmonary physicians; how­
ever, for this study, we included only the most basal 
lung function tests and omitted tests, such as exer­
cise testing. These tests are not always needed to 
confirm a diagnosis of asthma or COPD. We believe 
that the protocol discussed herein could easily be fol­
lowed by GPs or hospital physician assistants so long 
as they have access to these basic tests, thus, leading 
to potentially more health-care savings.
As we stated before, some physicians have used the 
protocol-driven lung function protocol that we devel­
oped approximately three years prior to this study. The 
author of this study and two other physicians have pri­
marily followed the protocol-driven testing strategy. 
Two other physicians (one senior and one junior) did 
not im plem ent this protocol-driven testing strategy 
because they were not convinced of the ability of this 
protocol to save time and cost.
We all agreed to perform this study, and the behavior 
of these two physicians did change after the completion 
of this study.
Trainees stay for four years in our hospital, and, at the 
time of the study, we had five trainees in all stages of 
their educational processes. We asked our trainees to 
order according to a test-protocol rather than at their 
own discretion. We advised them  that this would be 
more efficient.
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The protocol allows pulmonary function assistants to 
work more efficiently, which decreases the frequency 
that they need to interrupt the doctor, who will often be 
in a consultation. The workflow is based on our national 
guideline, which resembles the international guidelines 
of the ERS.
Steroid tests would not have added value to the diag­
nostic workflow in our patient group; hence, we 
doubted the need for such a test in a routine setting. 
After this study, we removed the steroid tests from the 
PFT protocol.
The total time in days to diagnosis was not different 
between the two groups; however, without waiting lists 
for the outpatient department and for PFT's, we believe 
there will be a difference in time between the CG and 
the EG that favors the EG.
We want to emphasize that international guidelines 
and several national guidelines do not recommend rever­
sibility testing as a means to distinguish asthma from 
COPD, other than when lung function returns to normal 
limits. We used three pulmonary function groups as an 
intermediate; however, the final diagnosis of asthma or 
COPD (or both) can only be made when the full clinical 
context, in which PFTs are only a part, is considered.
The prediction threshold of 9% is not a commonly 
accepted threshold for distinguishing asthm a from 
COPD. We only use this criterion to distinguish 
between the "non-reversible obstructive" and "partly- 
reversible obstructive" PFT groups. Internationally, this 
is merely one method that can be used to make this dis­
tinction between these subgroups, and no consensus is 
available regarding which criterion is the best [6].
A weakness in our study is the potential of a 
Hawthorne effect. The knowledge that they were 
involved in a trial may have affected the physicians' 
behavior (test ordering, making a final diagnosis). The 
only way to avoid this problem is to retrospectively con­
duct the study, which would challenge its internal valid­
ity. Therefore, we decided to conduct a random, parallel 
design so as to ensure internal validity (equivalence 
between groups, minimal likelihood of confounding); 
however, to the extent that our study suffered from a 
potential Hawthorne effect, this will most likely have 
resulted in an under-estimation of the impact of proto­
col-guided test ordering.
In order to minimize the impact of a potential 
Hawthorne effect, we discussed all of the results within 
our group after the inclusion period. Some doctors wanted 
to minimize patient return visits and ordered tests, which 
were regarded to be unnecessary during the second visit.
Conclusion
Problem-orientated PFT ordering significantly reduces 
the num ber of PFTs, the total cost, and the number
of outpatien t visits in the diagnosis of asthm a and 
COPD.
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